75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Discontinued Operations and Divestiture link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Collaboration Agreements, License Agreement and Revenues link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Consolidated Variable Interest Entity - Fortis link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Senior Secured Term Loan Facilities link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Liability Related to Sale of Future Revenues link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - FibroGen Cayman Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - At-the-Market Program link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Discontinued Operations and Divestiture (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Collaboration Agreements, License Agreement and Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Exclusive License and Option to Acquire Fortis Therapeutics (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Consolidated Variable Interest Entity - Fortis (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Senior Secured Term Loan Facilities (Table) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Liability Related to Sale of Future Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Significant Accounting Policies - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Discontinued Operations and Divestiture - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Discontinued Operations and Divestiture - Schedule of Financial Results of Discontinued Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Discontinued Operations and Divestiture - Schedule of Carrying Value of Assets and Liabilities of Discontinued Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Discontinued Operations and Divestiture - Schedule of Carrying Value of Assets and Liabilities of Discontinued Operations (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Discontinued Operations and Divestiture - Schedule of Carrying Value of Assets and Liabilities of Discontinued Operations (Detail) 3 link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Discontinued Operations and Divestiture - Schedule of Carrying Value of Assets and Liabilities of Discontinued Operations (Detail) 4 link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Discontinued Operations and Divestiture - Schedule of Significant Non-cash Items and Capital Expenditures for Discontinued Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Leases - Additioinal Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Consolidated Variable Interest Entity - Fortis - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Balance Sheet Components - Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position (Detail) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Senior Secured Term Loan Facilities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Liability Related to Sale of Future Revenues - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Liability Related to Sale of Future Revenues - Schedule of Activities of Liability Related to Sale of Future Revenues (Detail) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - FibroGen Cayman Non-Controlling Interests - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Stock-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Stock-Based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Subsequent Event - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Payment To Divestiture Of Businesses Payment to divestiture of businesses Cash paid related to divestiture Cash paid related to divestiture Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Loss from continuing operations Description of operations policy. Description Of Operations Policy Policy [Text Block] Description of Operations Clinical development milestone. Clinical Development Milestones [Member] Clinical and Development Milestone [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of presentation and principles of consolidation policy. Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block] Basis of Presentation and Principles of Consolidation Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Balance Sheet Location [Domain] Balance Sheet Location Disposal Group, Including Discontinued Operation, Inventory, Current Inventories Debt Instrument, Premium and Fees Debt instrument, premium and fees. Premium and fees API shipment. A P I Shipment [Member] API Shipment [Member] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total HiFiBiO agreement. Hi Fi Bi O Agreement [Member] HiFiBiO Agreement [Member] Revenue resulting from changes to estimated variable consideration. Revenue Resulting from Changes to Estimated Variable Consideration Revenue resulting from changes to estimated variable consideration Astellas agreements. Astellas Collaboration Agreement [Member] Astellas Agreement [Member] Schedule of Long-Term Debt Instruments [Table Text Block] Summary of Senior Secured Term Loan Facilities Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value Other, Shares Stockholders' Equity, Other Shares Entity Current Reporting Status Entity Current Reporting Status JAPAN Japan [Member] Dividends Payable, Amount Per Share Dividends per share Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Accounts receivable, net Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Shares Authorized Common stock, shares authorized Disposal group, including discontinued operation, cumulative currency translation adjustments. Disposal Group, Including Discontinued Operation, Cumulative Currency Translation Adjustments Discontinued operatiion cumulative currency translation adjustments Product and Service [Axis] Product and Service Document Fiscal Period Focus Document Fiscal Period Focus Revenue from Contract with Customer [Abstract] Revenue: Entity Shell Company Entity Shell Company Other Accrued Liabilities, Current Other SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type Cash and Cash Equivalent Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and cash equivalents Total cash and cash equivalents Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted average shares used to compute net income (loss) per share: Weighted average number of common shares used to calculate net income (loss) per share: Accrued Product Development Costs Excluding Interest. Accrued Product Development Costs Excluding Interest Accrued product development costs excluding interest Drug product revenue. Drug Product Revenue [Member] Drug Product Revenue, Net [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Recently issued accounting guidance not yet adopted. Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block] Recently Issued Accounting Guidance Not Yet Adopted Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Statement [Table] Statement [Table] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased Noncontrolling Interest [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average estimated fair value Disposal Group, Including Discontinued Operation, Cash Consideration Disposal group, including discontinued operation, cash consideration. Purchase price in cash Discontinued operation consideration in cash Statement [Line Items] Statement [Line Items] Business Combination [Domain] Business Acquisition, Acquiree Nonconsolidated Investees, Other [Member] Nonredeemable NCI [Member] Debt instrument accrued interest. Debt Instrument Accrued Interest Accrued interest Entity Filer Category Entity Filer Category Variable Interest Entity Disclosure [Text Block] Equity method investment - Variable Interest Entity Consolidated Variable Interest Entity - Fortis Liabilities and Equity Total liabilities, redeemable non-controlling interests and deficit Debt Instrument [Line Items] Unrestricted cash and cash equivalent balance maintain in accounts. Unrestricted Cash And Cash Equivalent Balance Maintain In Accounts Unrestricted cash and cash equivalent balance required to maintain in accounts Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of goods sold Accrued API and bulk drug product price true-up current. Accrued API and bulk drug product price true-up current API and bulk drug product price true-up Reduction of drug product revenue from related party. Reduction Of Drug Product Revenue From Related Party Reduction of drug product revenue from related party Business Combination, Voting Equity Interest Acquired, Percentage Percentage of outstanding shares acquired Lessee, Operating Lease, Option to Terminate Payment cap date on or after January one two thousand twenty nine. Payment cap date on or after January one two thousand twenty nine [Member] Payment Cap Date on or after January 1, 2029 [Member] Cash and Cash Equivalents, Fair Value Disclosure Assets fair value disclosure US Government Securities, at Carrying Value U.S. government bonds Fair value assets level2 to level1 transfer amount. Fair Value Assets Level2 To Level1 Transfer Amount Transfers of assets from level 2 to 1 Employee stock options [Member] Manufacturing Costs Burdened manufacturing costs Available for Sale Investments Contractual Maturity Available for sale investments contractual maturity. Available for sale investments contractual maturities Geographical [Domain] Geographical Inventory, Finished Goods, Gross Finished goods Inventory, Finished Goods, Gross, Total Asset-Backed Securities [Member] Asset-backed securities [Member] Revenue Interest Financing Agreement. Revenue Interest Financing Agreement [Member] Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Accounts receivable net current related parties. Accounts Receivable Net Current Related Parties Accounts receivable from related parties Debt Issuance Costs, Net Issuance cost Debt Issuance Costs, Net, Total Contract with customer liability deduction. Contract With Customer Liability Deduction Deduction Payments for transaction costs related to sale of future revenues. Payments For Transaction Costs Related To Sale Of Future Revenues Transaction costs related to sale of future revenues Debt Instrument, Interest Rate During Period Interest rate per annum Repayments of finance lease liabilities. Repayments Of Finance Lease Liabilities Financing cash flows from finance leases Repayments of finance lease liabilities Significant Accounting Policies [Text Block] Significant Accounting Policies Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents Derecognized. Derecognized [Member] Other Than Temporary Impairment Loss Securities Available for Sale Other than temporary impairment loss securities available for sale. Other-than-temporary impairment loss Repayment description. Repayment Description Repayment description Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation Contract liabilities, Contract Liabilities [Member] Contract Liabilities [Member] Equity Securities [Member] Equity investments [Member] Increase (decrease) in operating lease liabilities, current. Increase Decrease In Operating Lease Liabilities Current Operating lease liabilities, current Investment, Name [Axis] Share-Based Payment Arrangement [Member] 2014 Employee Share Purchase Plan [Member] Due to related parties deferred revenue noncurrent. Due To Related Parties Deferred Revenue Noncurrent Deferred revenue non-current to related party Earnings Per Share, Basic Basic Net income (loss) per share - basic Net income (loss) per share - basic Disaggregation of Revenue [Table Text Block] Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net Discontinued operation hold back amount to offset final net cash adjustments Disposal group, including discontinued operation, hold back amount to offset final net cash adjustments Disposal group, including discontinued operation, hold back amount to offset final net cash adjustments. Development and other revenue. Other Revenue - Contract Manufacturing [Member] Development and Other Revenue [Member] Development Revenue [Member] Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts. Accrued Product Development Costs Product development obligations Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation adjustments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments Payment for Contingent Consideration Liability, Investing Activities Contingent payment associated with business acquisition Interest Income (Expense), Nonoperating, Net Total interest and other, net Other liabilities current due to related parties. Other Liabilities Current Due to Related Parties Accrued and other current liabilities to related party Liabilities, Current Total current liabilities Disposal Group, Including Discontinued Operation, Accounts Payable, Current Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable, net Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net income (loss) to net cash used in operating activities: Debt financing agreement. Debt Financing Agreement [Member] Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Restructuring plan, expected reduction to workforce, percentage Entity Small Business Entity Small Business Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Accumulated deficit Retained Earnings (Accumulated Deficit), Total Accounts payable to related party Accounts Payable Related Party Current Accounts Payable Related Party Current Nonmonetary Transaction Type [Axis] Liability related to sale of revenues noncurrent. Liability Related To Sale Of Revenues NonCurrent Liability related to sale of future revenues, non-current Liquidity And Going Concern Policy Text Block Liquidity And Going Concern Policy Text Block Liquidity and Going Concern Accrued and other current liabilities Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Noncurrent Disposal group including discontinued operation accounts payable and accrued liabilities noncurrent. Cost, Product and Service [Extensible Enumeration] Cost, Product and Service [Extensible List] Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated Amortization, Debt Issuance Costs Issuance costs, amortised Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Leases [Abstract] Contract with Customer, Liability Deferred Revenue Contract with Customer, Liability, Total Deferred revenue Deferred revenues from associated contracts Balance at December 31, 2025 Balance at March 31, 2026 Lessee, operating lease, expiration period Lessee Operating Lease Expiration Period Lessee, operating lease, expiration period. Lessee, Lease, Description [Line Items] Amendment Flag Amendment Flag Product and Service [Domain] Product and Service Net cash held in China. Net Cash Held in China [Member] Geographic Distribution, Foreign [Member] Foreign subsidiaries [Member] Discontinued operations name Discontinued Operation, Name The amount of additional consideration based on net sales of product as defined under a collaboration agreement. Additional Consideration Based On Net Sales Additional consideration based on net sales description Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions. Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan Delayed Draw Term Loan [Member] Delayed Draw Term Loan (DDTL) [Member] Proceeds from Sale, Maturity and Collection of Investments Proceeds from maturities of investments Proceeds from Sale, Maturity and Collection of Investments, Total Earnings Per Share, Policy [Policy Text Block] Net Income (Loss) per Share Net Loss per Share Disposal Group, Including Discontinued Operation, Assets, Current Total current assets held for sale Current assets held for sale Liabilities and Equity [Abstract] Liabilities, redeemable non-controlling interests and deficit Property taxes and other current. Property Taxes And Other Current Property taxes and other taxes Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash provided (used) in operating activities Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period. License Fees And Milestones Revenue License and milestone revenue from a related party Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock [Member] Deferred revenues from associated contracts. Deferred Revenues From Associated Contracts Deferred revenues from associated contracts Initial Term Loan [Member] Initial Term Loan [Member] Initial Term Loan [Member] Miscellaneous receivables. Miscellaneous Receivables Miscellaneous receivables Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-sale Securities [Line Items] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Entity Address, Address Line One Entity Address, Address Line One Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Transfers of assets out of level 3 Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Earnings Per Share [Abstract] Loss Contingency Accrual Loss Contingency Accrual, Ending Balance Loss Contingency Accrual, Beginning Balance Litigation settlement amount Non-cash interest expense related to drug product revenue Non-cash interest expense related to drug product revenue Non-cash interest expense related to drug product revenue Balance Sheet Location [Axis] Balance Sheet Location Investment Type [Axis] Investment Type Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Operating lease right-of-use assets, net Debt Securities, Available-for-Sale, Unrealized Loss Position Available for sale securities in continual unrealized loss position, estimated fair value Available for sale securities in continual unrealized loss position, estimated fair value Payments to Acquire Debt Securities, Available-for-Sale Purchases of available-for-sale securities Purchases of available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Change in unrealized gain or loss on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Prepayment amount. Prepayment amount Prepayment amount of 2024 to 2030 Recognized as Revenue (Discontinued Operations) Disposal Group, Including Discontinued Operation, Revenue Product revenue, net Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Reduction to nonredeemable noncontrolling interests Reduction To Nonredeemable Noncontrolling Interests Reduction to nonredeemable noncontrolling interests. Disposal Group, Including Discontinued Operation, Assets [Abstract] Assets Investments, Debt and Equity Securities [Abstract] Valuation Approach and Technique [Axis] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash and cash equivalents Subsequent Event Type [Domain] Beijing Kangda Yongfu Pharmaceutical Co., LTD. Beijing Kangda Yongfu Pharmaceutical Co L T D [Member] Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares outstanding Anti-dilutive securities excluded from computation of net loss per share Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Other assets Minority Interest [Member] Minority interest. Minority Shareholders [Member] Impairment of property and equipment Impairment of Long-Lived Assets to be Disposed of Common Stock, Par or Stated Value Per Share Common stock, par value Money Market Funds, at Carrying Value Money market funds Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Amortized Cost Debt Securities, Available-for-Sale Estimated Fair Value Fair Value Investments Contract With Customer Liability [Table] Contract With Customer Liability [Table] Contract With Customer Liability [Table] Gain (Loss) on Termination of Lease Gain on lease termination Debt Disclosure [Abstract] Disposal Group, Including Discontinued Operation, Cash Payable at Closing Subject to Holdbacks Disposal group, including discontinued operation, cash payable at closing subject to holdbacks. Discontinued operation cash payable at closing subject to holdbacks Contract with customer liability net of balance presented against contract asset. Contract with customer liability net of balance presented against contract asset Balance Presented Net Against Contract Asset Accrued Liabilities, Current Total accrued and other current liabilities Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Ownership [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Long-Term Debt Instruments [Table] Restricted Cash and Cash Equivalent, Noncurrent Restricted time deposits Restricted Cash and Cash Equivalents, Noncurrent, Total Document Quarterly Report Document Quarterly Report Percentage of revenue interest on global net sales. Percentage Of Revenue Interest On Global Net Sales Percentage of revenue interest on global net sales Entity Address, State or Province Entity Address, State or Province Co development information sharing and committee services. Co Development Information Sharing And Committee Services [Member] Co-development, information sharing & committee services [Member] Investment, Name [Domain] Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Holding Gains Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations and Divestiture Geographical [Axis] Geographical Contract with Customer, Liability, Revenue Recognized Recognized as Revenue Royalty revenue recognized as drug product revenue Milestone payments [Member] Milestone payments. Discontinued Operations, Policy [Policy Text Block] Discontinued Operations Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Percentage of outstanding shares owned Raw materials Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross, Total Disposal Group Including Discontinued Operation Additional Payment Following Final Net Cash Adjustments after Closing Disposal group including discontinued operation additional payment following final net cash adjustments after closing. Disposal group including discontinued operation additional payment following final net cash adjustments after closing License [Member] License Revenue [Member] License [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Recorded Stock-Based Compensation Expense Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss): Income (Loss) from Continuing Operations, Per Basic Share Loss from continuing operations per share - basic Subsequent Event [Member] Subsequent Event [Member] Redemption Of Fractional Shares Due To Reverse Stock Split Value Redemption of fractional shares due to reverse stock split value. Redemption of fractional shares due to reverse stock split Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee Billed Contracts Receivable Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Disposal Group Including Discontinued Operation Interest Income And Other Expenses Net Disposal group including discontinued operation interest income and other expenses net. Interest income and other income (expenses), net Interest income and other income (expenses), net Antidilutive Securities [Axis] NovaQuest Capital Management. NovaQuest Capital Management [Member] Interest Expense, Debt Interest expense Interest Expense, Debt, Total AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss [Member] Adjustments to additional paid in capital Adjustments To Additional Paid In Capital Adjustments to additional paid in capital. Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Due to related parties deferred revenue current. Due To Related Parties Deferred Revenue Current Deferred revenue current to related party Drug product revenue from related party. Drug Product Revenue From Related Party Drug product revenue from a related party Total long-term assets held for sale Disposal Group, Including Discontinued Operation, Assets, Noncurrent Long-term assets held for sale AstraZeneca AB. Astra Zeneca [Member] AstraZenecaAB [Member] Recently issued and adopted accounting guidance. Recently Issued And Adopted Accounting Guidance Policy [Text Block] Recently Issued and Adopted Accounting Guidance Business Combination, Consideration Transferred Purchase consideration Business Combination, Consideration Transferred, Total Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025 Maximum payment cap amount. Maximum payment cap amount Maximum payment cap amount Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of Financial Results, Carrying Value of Assets and Liabilities and Significant Non-Cash Items and Capital Expenditures of Discontinued Operations Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Debt Instrument, Maturity Date Maturity date Other liabilities noncurrent due to related parties. Other Liabilities Noncurrent Due to Related Parties Due to related parties, noncurrent Minimum [Member] Minimum [Member] Financial Instrument [Axis] Assets, Current [Abstract] Current assets: Equity Method Investments [Table Text Block] Summary of Equity Method Investment Collaborative arrangement and revenues. Collaborative Arrangement And Revenues Policy [Text Block] Collaboration Arrangements and Revenues Fair value of US treasury notes and bills transfered from level one to level two. Fair Value Of US Treasury Notes And Bills Transfered From Level One To Level Two Fair value of U.S. treasury notes and bills transfered from level 1 to level 2 Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Astellas agreement. Astellas Agreement [Member] Astellas Agreement [Member] Segment Reporting [Abstract] Manufacture and supply of pamrevlumab. Manufacture And Supply Of Pamrevlumab [Member] Manufacture and Supply of Pamrevlumab [Member] Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Values of Financial Assets Measured on Recurring Basis Liabilities, Current [Abstract] Current liabilities: Increase (decrease) in operating lease right-of-use assets. Increase Decrease In Operating Lease Right Of Use Assets Operating lease right-of-use assets Product [Member] Product Revenue, Net [Member] Product [Member] Increase (decrease) in accrued interest expense related to sale of future revenues Increase Decrease In Accrued Interest Expense Related To Sale Of Future Revenues Accrued interest expense related to sale of future revenues Related Party Transactions [Abstract] Represents the amount of milestone payments related to commercial sales under the collaborative agreement. Commercial Sales Milestone Commercial sales milestone Shares, Outstanding Balance, Shares Balance, Shares Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable from related parties Accounts receivable, net Liability related to sale of revenue current. Liability Related To Sale Of Revenue Current Less: Current portion classified to accrued and other current liabilities Prepaid Supplies Contract assets Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Liabilities Commitments and Contingencies Commitments and Contingencies SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves Work-in-progress Inventory, Work in Process, Gross The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. Cash Consideration Received Under Collaboration Agreement Total Consideration Cash Consideration Received Under Collaboration Agreement Total Consideration Operating Lease, Liability Operating lease liability Operating Lease, Liability, Total Present value of lease liabilities Reverse stock split Stockholders' Equity, Reverse Stock Split Forecast [Member] Forecast [Member] Provision for Other Credit Losses Credit related losses Category of Item Purchased [Axis] Category of Item Purchased Disposal group including discontinued operation interest and other net. Disposal Group Including Discontinued Operation Interest And Other Net [Abstract] Interest and other, net Payment to options exercised Payment to Options Exercised Payment to options exercised Lessee, Lease, Description [Table] Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of exchange rate change on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net income (loss) Nonredeemable Preferred Stock [Member] Nonredeemable [Member] Total current liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities held for sale Asset acquisition policy. Asset Acquisition Policy [Policy Text Block] Asset Acquisition Disposal Group, Including Discontinued Operation, Operating Expense Total operating costs and expenses Geographic Distribution [Axis] Geographic Distribution Long-Term Debt, Type [Domain] Regulatory milestone. Regulatory Milestones [Member] Regulatory Milestone [Member] Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Basic, Total Basic Scenario [Axis] Other Stockholders' Equity, Other Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses Income before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income (loss) before income taxes Accrued Interest Interest Payable Astellas Europe Agreement. Astellas Europe Agreement [Member] Astellas Europe Agreement [Member] Accrued co-promotion expenses - current Accrued co-promotion expenses - current. Accrued Co Promotion Expenses Current Subsequent Events [Text Block] Subsequent Event Long-Term Debt Term loan Senior secured term loan facilities, ending balance Related Party Transactions Disclosure [Text Block] Related Party Transactions Cash Cash, Ending Balance Cash, Beginning Balance Cash Interest expense related to sale of future revenues Non cash interest expense related to sale of future revenues. Non Cash Interest Expense Related To Sale Of Future Revenues Interest expense recognized APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Disposal group, including discontinued operation, consideration transaction costs and fees Disposal group, including discontinued operation, consideration transaction costs and fees. Discontinued operation consideration transaction costs and fees Equity, Attributable to Parent Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total stockholders' deficit attributable to Kyntra Bio Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Share Purchase Agreement [Member] Share purchase agreement. Product Development Costs Product Development Costs Product development obligations Statement of Stockholders' Equity [Abstract] Mark Eisner [Member] Mark Eisner. Equity Method Investments Ending balance Beginning balance Equity method investment in unconsolidated variable interest entity Equity method investments Valuation Approach and Technique [Domain] Series A Preferred Stock [Member] Series A Preferred Shares [Member] Use of Estimates, Policy [Policy Text Block] Use of Estimates Reverse Stock Split [Member] Reverse Stock Split [Member] Collaborative Arrangement [Member] Collaborative Arrangement [Member] Product revenue policy. Product Revenue Policy Policy [Text Block] Product Revenue, Net Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair Value Measurements Drug product revenue. Drug Product Revenue Policy [Text Block] Drug Product Revenue, Net Accrued liabilities paid Accrued Liabilities Paid Accrued liabilities paid. Interest paid related to sale of future revenues. Interest Paid Related to Sale of Future Revenues Interest paid Interest paid Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. Development And Regulatory Approval Milestones Development and regulatory approval milestones U.S. [Member] UNITED STATES Noncontrolling Interest [Member] Noncontrolling Interests [Member] Minority Shareholders [Member] Liability related to sale of future revenue. Liability Related To Sale of Future Revenue [Text Block] Liability Related to Sale of Future Revenues Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued and Other Current Liabilities Debt Instrument, Name [Domain] Other Assets, Current Other current assets Measurement Input, Discount Rate [Member] Measurement Input Discount Rate [Member] Accrued Liabilities and Other Liabilities Accrued and other current liabilities ($45,870 and $39,814 to a related party) Accrued Liabilities and Other Liabilities, Total Accrued and other current liabilities Investment income Investment income in unconsolidated variable interest entity Income (Loss) from Equity Method Investments, Total Investment income (loss) Investment loss Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total Income (loss) from discontinued operations per share - basic Description of discontinued operations Disposal Group, Including Discontinued Operation, Description and Timing of Disposal Disposal Group Including Discontinued Operation Equity Method Investment In Unconsolidated Variable Interest Entity Disposal Group Including Discontinued Operation Equity Method Investment In Unconsolidated Variable Interest Entity. Equity method investment in unconsolidated variable interest entity Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Other assets Interest Expense Interest Expense, Total Interest expense Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Entity [Domain] Equity Method Investment, Ownership Percentage Ownership Percentage Ownership percentage Accrued restructuring charges. Accrued Restructuring Charges Accrued restructuring charges Shares issued from stock plans net of payroll taxes paid shares. Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares Shares issued from stock plans, net of payroll taxes paid, Shares Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. Potential Milestones Potential milestone payments Related Party, Type [Axis] Related Party Nonredeemable Noncontrolling Interest Nonredeemable non-controlling interests Disposal Group Name [Domain] Disposal Group Including Discontinued Operation Revenue [Abstract] Disposal group including discontinued operation revenue. Revenue: Entity Address, City or Town Entity Address, City or Town Civil penalty payment Loss Contingency, Civil Penalty Payment Loss contingency, civil penalty payment. Number of Reportable Segments Number of reportable segment Security Exchange Name Security Exchange Name Europe [Member] Europe [Member] Redeemable Noncontrolling Interest, Equity, Carrying Amount Redeemable non-controlling interests Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. Proceeds From Upfront Non Contingent And Time Based Payments Upfront, non-contingent and time-based payments received Long-Term Debt, Gross Principal of senior secured term loan facilities Initial term loan amount Drug product revenue, net. Drug Product Revenue, Net [Member] Counterparty Name [Axis] Convertible promissory note. Convertible promissory note [Member] Convertible promissory note [Member] Shanghai and Beijing China. Shanghai and Beijing China [Member] Shanghai and Beijing, China [Member] Measurement Input Type [Domain] Antidilutive Securities, Name [Domain] Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total Income (loss) from discontinued operations per share - diluted Stockholders' Equity Note [Abstract] Inventory, Net Inventories Total inventories Future revenue granted. Future revenue granted Future revenue granted Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue. Collaboration Services And Other Revenue Collaboration services and other revenue from a related party Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Statistical Measurement [Domain] Statistical Measurement Payment cap date on or before December thirty one two thousand twenty eight. Payment cap date on or before December thirty one two thousand twenty eight [Member] Payment Cap Date on or before December 31, 2028 [Member] Assets, Current Total current assets Share-Based Payment Arrangement, Expense Total stock-based compensation expense Document Period End Date Document Period End Date Collaborative arrangement and revenues. Collaborative Arrangement And Revenues Disclosure [Text Block] Collaboration Agreements, License Agreement and Revenues Operating lease liabilities, non-current Disposal Group Including Discontinued Operation Operating Lease Liability Noncurrent Disposal group including discontinued operation operating lease liability noncurrent. Astra Zeneca agreements. Astra Zeneca Agreements [Member] AstraZeneca Agreements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Holdback consideration receivable related to divestiture Holdback consideration receivable related to divestiture Statement of Financial Position [Abstract] Accrued restructuring charge current. Accrued Restructuring Charge Current Accrued restructuring charge FibroGen International [Member] FibroGen international. FibroGen International [Member] Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Preclinical And Clinical Trial Current Preclinical and clinical trial accruals Lessee, Operating Lease, Existence of Option to Terminate [true false] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Cash received for sale of discontinued operation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Class of Stock [Axis] Closing of Divestiture of FibroGen International [Member] Closing of Divestiture of FibroGen International, member. Closing of Divestiture of FibroGen International [Member] Effective Annual Interest Rate Related To Sale Of Future Revenues Effective Annual Interest Rate Related To Sale Of Future Revenues Effective annual interest rate related to sale of future revenues Total liabilities Liabilities Operating Costs and Expenses [Abstract] Operating costs and expenses: Proceeds from Divestiture of Businesses, Net of Cash Divested Proceeds from Divestiture of Businesses, Net of Cash Divested, Total Proceeds from divestiture, net of cash transferred Financial Instruments [Domain] Christine Chung [Member] Christine Chung. Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Increase (Decrease) in Deferred Revenue Decrease in revenue Increase in revenue Contract with customer liability. Contract With Customer Liability [Line Items] Contract with Customer Liability [Line Items] Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale Other impairment loss Accrued Inventory Cost Accrued inventory cost. Inventory cost related Accrued inventory related cost Dividends Dividends, Total Total dividends distributed Disposal Groups, Including Discontinued Operations [Table] Finance Lease, Right-of-Use Asset, Amortization Amortization of finance lease right-of-use assets Amortization of right-of-use assets Prepaid Expense and Other Assets, Current [Abstract] Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses Weighted Average Number of Shares Outstanding, Diluted Diluted Diluted Diluted Securities Act File Number Entity File Number Payment cap date after January one two thousand thirty. Payment cap date after January one two thousand thirty [Member] Payment Cap Date after January 1, 2030 [Member] OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gain (loss) on investments, net of tax effect Cover [Abstract] Fortis Therapeutics. Fortis Therapeutics [Member] Fortis Therapeutics [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Measurement Input Type [Axis] Discontinued operation other receivable Disposal Group, Including Discontinued Operation, Other Receivable Disposal group, including discontinued operation other receivable. Prepaid Expense and Other Assets, Current Total prepaid expenses and other current assets Prepaid expenses and other current assets Agency bonds. Agency Bonds [Member] Agency bonds [Member] Increase (decrease) in operating lease liabilities, non-current. Increase Decrease In Operating Lease Liabilities Non Current Operating lease liabilities, non-current Investments [Domain] Investments Loss Contingency, Receivable, Current Litigation settlement receivable Loss Contingency, Receivable, Current Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Accounting policy. Accounting Policy [Line Items] Accounting Policy [Line Items] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss before income taxes Loss from continuing operations before income taxes Scenario [Domain] Payment Period One [Member] Payment Period One [Member] Number of Operating Segments Number of operating segment Segment Information Segment Reporting Disclosure [Text Block] General and Administrative Expense General and administrative General and Administrative Expense, Total Noncontrolling Interest [Line Items] Litigation settlement current. Litigation Settlement Current Litigation settlement Investment Income, Dividend Dividend received Dividend Received Dividend Received Falikang. Falikang [Member] Falikang [Member] Disposal group, including discontinued operation, hold back amount to satisfy any indemnity claims Disposal group, including discontinued operation, hold back amount to satisfy any indemnity claims. Discontinued operation, hold back amount to satisfy any indemnity claims Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Loss on debt extinguishments Loss on debt extinguishments Loss on debt extinguishments Restructuring Charges Restructuring plan, non-recurring charges Restructuring Charges, Total Restructuring charge Schedule of Investments [Table] Disposal Group Including Discontinued Operation Investment Income In Unconsolidated Variable Interest Entity Disposal group including discontinued operation investment income in unconsolidated variable interest entity. Investment income in unconsolidated variable interest entity Investment income in unconsolidated variable interest entity Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Profit share liability Deferred Revenue Deferred revenue Development revenue. Development Revenue [Member] Ownership [Axis] Other investors. Other Investors [Member] FibroGen Cayman. Fibro Gen Cayman [Member] FibroGen Cayman [Member] Discontinued operation consideration Disposal Group, Including Discontinued Operation, Consideration Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Depreciation Depreciation Depreciation, Total Long-Term Investments Long-Term Investments, Total Long-term investments Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding (in shares) Common stock, shares outstanding Operating Lease, Liability, Current Operating lease liabilities, current Operating lease liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Contract with customer milestone method. Contract With Customer Milestone Method Table [Text Block] Summary of License Revenue and Development Revenue Recognized under Agreement Document Transition Report Document Transition Report Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Short-Term Investments Short-term investments Short-term Investments, Total Accrued Liabilities, Current [Abstract] Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Research and Development Expense Research and development Research and Development Expense, Total Acquired in-process research and development expenses Cumulative currency translation adjustment attributable to divestiture (Note 2) Cumulative Currency Translation Adjustment Attributable to Divestiture Cumulative currency translation adjustment attributable to divestiture. Cumulative currency translation adjustment attributable to divestiture General Purchases And Other Programs [Member] General Purchases And Other Programs [Member] General purchases and other programs. Cost of Revenue Cost of goods sold Cost of Revenue, Total Related cost of goods sold Valuation Technique, Discounted Cash Flow [Member] Discounted Cash Flow [Member] Schedule of Investments [Abstract] Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid. Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares issued from stock plans, net of payroll taxes paid Statement of Cash Flows [Abstract] Stock Issued During Period, Value, New Issues Issuance cost under ATM Program Issuance cost under ATM Program Equity [Text Block] At-the-Market Program Number of product development obligations. Number Of Product Development Obligations Number of product development obligations Discontinued Operations and Disposal Groups [Abstract] Net income (loss) Net income (loss) Direct sales. Direct Sales [Member] Direct Sales [Member] Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Inventories Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Revenue interest payment. Revenue interest payment Revenue interest payment Beijing Falikang Pharmaceutical Co. Ltd. Beijing Falikang Pharmaceutical Co Ltd [Member] Beijing Falikang Pharmaceutical Co Ltd Beijing Falikang Pharmaceutical Co. Ltd [Member] Accrual for Taxes Other than Income Taxes, Current Value added taxes and other taxes Assets [Abstract] Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Dividend received from unconsolidated variable interest entity. Dividend Received from Unconsolidated Variable Interest Entity Dividend received from unconsolidated variable interest entity Commercial Paper, at Carrying Value Commercial paper Document Fiscal Year Focus Document Fiscal Year Focus Liability related to sale of future revenues non current. Liability Related To Sale Of Future Revenues Non Current Liability related to sale of future revenues, non-current Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Investing activities Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Accounts payable Research and Development Expense [Member] Research and development [Member] Geographic Distribution [Domain] Geographic Distribution Fair value of US treasury notes and bills transfered from level one to level two. Fair Value Of Us Treasury Notes And Bills Transfered From Level One To Level Two1 Fair value of U.S. treasury notes and bills transfered from level 1 to level 2 Gain (Loss) on Disposition of Business Loss on divestiture Loss on divestiture Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Roll-forward of Related Contract Liabilities Operating lease liabilities, current Disposal Group Including Discontinued Operation Other Liabilities current Disposal group including discontinued operation other liabilities current. Deferred Revenue Deferred Revenue, Total Deferred revenue Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of Prepaid Expenses and Other Current Assets Transaction Type [Axis] Transaction Type Research and pre-clinical stage development programs. Research And Pre Clinical Stage Development Programs [Member] Research and Preclinical Stage Development Programs [Member] Supplies, net. Supplies Net Net unbilled co-development revenue Net contract assets Net unbilled milestone and co-development revenue Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue. Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue Aggregate consideration received excluding drug product revenue RSUs, PRSUs and TSR Awards [Member] RSUs, PRSUs and TSR Awards [Member] RSUs, PRSUs and TSR awards [Member] Bond and mutual funds. Bond And Mutual Funds [Member] Bond and mutual funds [Member] Other Liabilities Due to related parties Other Liabilities, Total Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Disposal Group Including Discontinued Operation Hold Back Amount Received As Final Net Cash Adjustments Disposal group including discontinued operation hold back amount received as final net cash adjustments. Discontinued operation hold back amount received as final net cash adjustments Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Lease termination settlement amount one time payment. Lease Termination Settlement Amount One Time Payment Lease termination settlement one time cash payment Third party shareholders. Third Party Shareholders [Member] Disposal Group, Including Discontinued Operation, Interest Expense Interest expense Interest expense Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Lease termination, remaining security deposit Long-Term Line of Credit, Total Long-Term Line of Credit Debt Instrument [Axis] Share-Based Payment Arrangement [Abstract] Assets, Fair Value Disclosure Total fair value of financial assets Assets, Fair Value Disclosure, Total Revenues Revenues from related parties Revenues, Total Revenues Interest Expense, Term Loan Interest Expense, Term Loan Outstanding interest amount Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided (used) by investing activities Variable consideration payment received from estimated future co-development billing. Variable Consideration Payment Received From Estimated Future Co Development Billing Transaction price, variable consideration from estimated future co-development billing Transaction price, variable consideration from estimated future co-development billing Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Transfers of assets into level 3 Title of 12(b) Security Title of 12(b) Security Lease termination related. Lease Termination Related Lease termination related Money Market Funds [Member] Money market funds [Member] Related Party, Type [Domain] Related Party Income Tax Disclosure [Text Block] Income Taxes Restructuring charge. Restructuring Charge [Policy Text Block] Restructuring charge Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Disposal Group Including Discontinued Operation Interest And Other Net Disposal group including discontinued operation interest and other net. Total interest and other, net Other Liabilities, Noncurrent Total other long-term liabilities Other long-term liabilities Other long-term liabilities Legal Entity [Axis] Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Income Tax Disclosure [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Bonds [Member] Agency bonds [Member] Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Reduction of accrued and other current liabilities Transaction price allocated to performance obligations. Transaction Price Allocated To Performance Obligations Transaction price and allocated to performance obligations Measurement Frequency [Domain] Measurement Frequency Nonmonetary Transaction Type [Domain] Income Statement Location [Axis] Income Statement Location Trading Symbol Trading Symbol Liability related to sale of future revenues - ending balance Liability related to sale of future revenues - beginning balance Liability related to sale of future revenues. Liability Related To Sale Of Future Revenues Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Disposal group, including discontinued operation, derecognition of net equity Disposal group, including discontinued operation, derecognition of net equity. Discontinued operation derecognition of net equity Subsequent Event Type [Axis] Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Employee-related Liabilities, Current Payroll and related accruals Employee-related Liabilities, Current, Total Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Fair Value, Recurring [Member] Fair Value, Measurements, Recurring [Member] Other Impairment Loss Securities Available for Sale Other impairment loss securities available for sale. Other impairment loss Noncontrolling Interest Disclosure [Text Block] FibroGen Cayman Non-Controlling Interests Juan Graham [Member] Juan Graham. Selling and Marketing Expense Sales and marketing Selling and Marketing Expense, Total Prepaid expenses and other current assets from a related party Prepaid expense and other assets current related party. Prepaid Expense And Other Assets Current Related Party Equity Components [Axis] Equity Components Accounts Payable Accounts payable Accounts Payable, Total Nonoperating Income (Expense) Interest income and other income (expenses), net Interest income and other income (expenses), net Equity Component [Domain] Equity Component Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets Business Combination [Axis] Business Acquisition Redeemable Preferred Stock [Member] Redeemable [Member] Disposal Group Including Discontinued Operation Research And Development Expense Disposal group including discontinued operation research and development expense. Research and development Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. Percentage Of Funding For Costs Percentage of joint development costs committed to fund Disposal Group Including Discontinued Operation Operating Lease Right Of Use Asset Noncurrent Disposal group including discontinued operation operating lease right of use asset noncurrent. Operating lease right-of-use assets Contract with customer liability additions. Contract With Customer Liability Additions Additions US Treasury and Government [Member] U.S. government bonds [Member] Statement of Comprehensive Income [Abstract] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Maximum [Member] Maximum [Member] Collaboration agreement payment Collaboration agreement payment. Statistical Measurement [Axis] Statistical Measurement Contract with Customer, Liability, Noncurrent Deferred revenue, net of current Deferred revenue, net of current Prepaid Expense, Current Prepaid assets Prepaid Expense, Current, Total Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2026 and December 31, 2025; 4,048 and 4,047 shares issued and outstanding at March 31, 2026 and December 31, 2025 Disposal Group Including Discontinued Operation Costs And Expenses [Abstract] Disposal group including discontinued operation costs and expenses. Operating costs and expenses: Cash and Cash Equivalents [Abstract] Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total deficit Royalty [Member] Royalty Revenue [Member] United States/Rest of World and China. United States Rest Of World And China [Member] U.S./RoW and China [Member] License agreement with Eluminex. License Agreement With Eluminex [Member] Eluminex [Member] Eluminex Agreements [Member] Fair Value Assets Level1 To Level2 Transfer Amount Fair value assets level1 to level2 transfer amount. Transfers of assets from level 1 to 2 Income (Loss) from Continuing Operations, Per Diluted Share Loss from continuing operations per share - diluted Accrued Liabilities Accrued liabilities Accrued Liabilities, Total Related accrued liabilities Amortization of Debt Issuance Costs Amortization of issuance costs Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Preferred Stock, Shares Authorized Preferred stock, shares authorized Costs and Expenses Total operating costs and expenses Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class Payment, Tax Withholding, Share-Based Payment Arrangement Cash paid for payroll taxes on restricted stock unit releases Liability related to sale of future royalties. Liability Related to Sale of Future Royalties [Abstract] Risks and uncertainties. Risks And Uncertainties Policy [Text Block] Risks and Uncertainties Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Available for sale securities in continual unrealized loss position, gross unrealized holding losses Available for sale securities in continual unrealized loss position, gross unrealized holding losses Available for sale securities in continual unrealized loss position, gross unrealized holding losses Astellas. Astellas [Member] Astellas [Member] Reverse Stock Split [Policy Text Block] Reverse stock split. Reverse Stock Split Related Party Transaction [Line Items] Related Party Transaction [Line Items] Employee Stock [Member] ESPP [Member] Business Combination [Table] Entity Registrant Name Entity Registrant Name Debt Disclosure [Text Block] Senior Secured Term Loan Facilities Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Holding Losses Gross Unrealized Holding Losses Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Changes in revenue from changes to estimated variable consideration Lease termination settlement amount. Lease Termination Settlement Amount Lease termination settlement amount Other Nonoperating Income (Expense) Other Other Nonoperating Income (Expense), Total Additional Paid in Capital Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional paid-in capital Additional Paid in Capital, Total Payment period two. Payment Period Two [Member] Subsequent Events [Abstract] Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit), Total Provision for (benefit from) income taxes Benefit from income taxes Measurement Frequency [Axis] Measurement Frequency Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] U.S. government bonds. U S Government Bonds [Member] U.S. government bonds [Member] Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Payments for Restructuring Cash payments for restructuring Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Schedule of drug product revenue. Schedule Of Drug Product Revenue Table [Text Block] Schedule of Drug Product Revenue Secured Long-Term Debt, Noncurrent Senior secured term loan facilities, non-current Assets Total assets Income Statement [Abstract] Percentage of revenue sold. Percentage of revenue sold Percentage of revenue sold Jeffrey Henderson [Member] Jeffrey Henderson. Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Selling, General and Administrative Expenses [Member] Selling, general and administrative [Member] Delayed draw term loan two. Delayed Draw Term Loan Two [Member] Delayed Draw Term Loan 2 Stock Issued During Period, Shares, New Issues Issuance cost under ATM Program , Shares Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation, Total Recorded unconditional purchase obligation Amortization of debt issuance costs and related transaction costs. Amortization of Debt Issuance Costs and Related Transaction Costs Issuance costs and related transaction costs, amortised Business Combination [Abstract] Earnings Per Share, Diluted Diluted Net income (loss) per share - diluted Net income (loss) per share - diluted Premiums and Other Receivables, Net Premium and fees Disaggregation of Revenue [Abstract] City Area Code City Area Code Disposal Group Including Discontinued Operation Investment Loss In Unconsolidated Variable Interest Entity Disposal group including discontinued operation investment loss in unconsolidated variable interest entity Investment loss in unconsolidated variable interest entity Investment loss in unconsolidated variable interest entity Other Comprehensive Income (Loss), Net of Tax Other comprehensive income, net of taxes Contract with customer, liability, increase (decrease) from current translation and other. Contract With Customer Liability Increase Decrease From Current Translation And Other Currency Translation and Other Disposal Group, Including Discontinued Operation, Cash Paid at Closing Disposal group, including discontinued operation, cash paid at closing. Discontinued operation cash paid at closing Revenue payment cap amount. Revenue Payment Cap Amount Revenue payment cap amount Debt Instrument, Fee Amount Paid to the Lenders Discontinued Operation, Tax Effect of Discontinued Operation Provision for income taxes Manufacture And Supply Of FG Three Two Four Six [Member] Manufacture and supply of FG three two four six. Manufacture And Supply Of FG - 3246 [Member] Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax Business Combination [Line Items] Counterparty Name [Domain] Foreign Government Debt [Member] Foreign government bonds [Member] Product revenue from a related party. Product Revenue Product revenue from a related party Disposal Group Name [Axis] Award Date [Axis] Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property and equipment, net Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Total long-term liabilities held for sale Long-term liabilities held for sale Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Total cash and cash equivalents at end of period Total cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Corporate Bond Securities [Member] Corporate bonds [Member] Operating Income (Loss) Loss from operations Award Date [Domain] Retained Earnings [Member] Accumulated Deficit [Member] Schedule of activity of liability related to sale of future revenues. Schedule Of Activity Of Liability Related To Sale Of Future Revenues [Table Text Block] Schedule of Activities of Liability Related to Sale of Future Revenues Transaction [Domain] Transaction Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Accrued profit share current. Accrued Profit Share Current Roxadustat profit share to AstraZeneca Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Operating lease liabilities Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Redemption of fractional shares due to reverse stock split, Shares Redemption of Fractional Shares Due to Reverse Stock Split Redemption of fractional shares due to reverse sock split. Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash used in financing activities Noncontrolling Interest, Increase (Decrease) from Distributions to Noncontrolling Interest Holders Noncontrolling interest, increase (decrease) from distributions to noncontrolling interest holders. Distribution to non-controlling interest (Note 9) Interest and other, net Nonoperating Income (Expense) [Abstract] Bulk drug product. Bulk Drug Product [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Agency bonds Agency Bonds, at Carrying Value Agency bonds, at carrying value. Manufacture and Supply of Roxadustat. Manufacture And Supply Of Roxadustat [Member] Manufacture and Supply of Roxadustat [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Entity Interactive Data Current Entity Interactive Data Current Increase (Decrease) in Contract with Customer, Liability Deferred revenues Income Statement Location [Domain] Income Statement Location Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Operating activities Investment (gain) loss in unconsolidated variable interest entity. Investment Gain Loss In Unconsolidated Variable Interest Entity Investment income in unconsolidated variable interest entity Investment income in unconsolidated variable interest entity Accretion (Amortization) of Discounts and Premiums, Investments Net accretion of premium and discount on investments Selling, general and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Leases. Leases Increase (Decrease) in Other Noncurrent Liabilities Other long-term liabilities accrued litigation settlement. Accrued Litigation Settlement Accrued litigation settlement Increase (decrease) in accrued interest for finance lease liabilities. Increase Decrease In Accrued Interest For Finance Lease Liabilities Accrued interest for finance lease liabilities Entity Tax Identification Number Entity Tax Identification Number Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' deficit: Long-Term Debt, Type [Axis] Accounting policy. Accounting Policy [Table] Accounting Policy [Table] Noncontrolling Interest Items [Abstract] Loss Contingency, New Claims Filed, Number Putative securities class action complaints filed Number of complaints filed Interest Income, Other Interest income Local Phone Number Local Phone Number Other Purchases. Other Purchases [Member] Other Purchases [Member] Liability related to sale of future revenues current. Liability Related To Sale Of Future Revenues Current Current portion of liability related to sale of future revenues CHINA China [Member] Payment of issuance cost under ATM Program Payments of Financing Costs Payments of Financing Costs, Total Payment of issuance cost under ATM Program Accounting Policies [Abstract] License and development. License And Development [Member] License and Development [Member] Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Summary of Amounts Recognized as Revenue Contract with customer liability reclassified to accrued liability. Contract With Customer Liability Reclassified to Accrued Liability Reclassified to Accrued Liability / Accounts Payable Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Drug product revenue recognized AstraZeneca. Astra Zeneca Astra Zeneca [Member] Outstanding interest and related premium and fees Outstanding interest and related premium and fees. Class of Stock [Domain] Commercial Paper [Member] Commercial paper [Member] Accrued Professional Fees, Current Professional services Entity Emerging Growth Company Entity Emerging Growth Company Income from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss)